Search Result

Results for "

Phosphodiesterase-IN-5

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (8) Autophagy (8) Bacterial (7) Calcium Channel (1) Collagen (1) Drug Derivative (4) Drug Metabolite (2) Endogenous Metabolite (16) GPR35 (1) Interleukin Related (1) Isotope-Labeled Compounds (11) Lipoxygenase (1) Na+/H+ Exchanger (NHE) (1) NO Synthase (6) Phosphodiesterase (PDE) (62) PKA (1) PKG (1) Reactive Oxygen Species (ROS) (1) Reference Standards (14) TNF Receptor (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (25) Endocrinology (27) Inflammation/Immunology (14) Metabolic Disease (15) Neurological Disease (10)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15025

Sildenafil Maximum Cited Publications 15 Publications Verification UK-92480	Phosphodiesterase (PDE) Autophagy Apoptosis Bacterial	Cardiovascular Disease Cancer
Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM.

HY-15025A

Sildenafil citrate Maximum Cited Publications 15 Publications Verification UK-92480 citrate	Phosphodiesterase (PDE) Autophagy Apoptosis Bacterial	Cardiovascular Disease Cancer
Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC₅₀ of 5.22 nM.

HY-134124

Glutathione ethyl ester	Reactive Oxygen Species (ROS)	Metabolic Disease
Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .

HY-B0442

Vardenafil 5 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B1816

Zaprinast 3 Publications Verification M&B 22948	Phosphodiesterase (PDE) GPR35	Cardiovascular Disease Neurological Disease Endocrinology
Zaprinast (M&B 22948) is a selective inhibitor of cGMP-selective *Phosphodiesterase (PDE5). Zaprinast causes a significant increase in cGMP levels in myocytes. Zaprinast is a G protein-coupled receptor 35 (GPR35)* agonist which activates rat GPR35 strongly and activates human GPR35 moderately. Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects .

HY-18252

Avanafil 1 Publications Verification TA1790	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) is a potent and selective **phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀** values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18253

Udenafil DA8159	Phosphodiesterase (PDE)	Endocrinology Cancer
Udenafil (DA8159) is a potent, selective and orally active **phosphodiesterase type 5 (PDE5)** inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research .

HY-B0442A

Vardenafil hydrochloride 5 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil hydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-117109

Amino Tadalafil	Drug Derivative	Others
Amino Tadalafil is a **phosphodiesterase type 5 (PDE5)** inhibitor analog and tadalafil structural analog. Amino Tadalafil can be specifically detected by anti-tadalafil polyclonal antibodies, with a cross-reactivity of 105.2% with tadalafil. Amino Tadalafil can be incorporated into dietary supplements .

HY-90009

Nortadalafil 1 Publications Verification Demethyl Tadalafil	Phosphodiesterase (PDE)	Cardiovascular Disease Neurological Disease Cancer
Nortadalafil (Demethyl Tadalafil) is a **phosphodiesterase-5 (PDE-5)** inhibitor and Tadalafil (HY-90009A) analog. Nortadalafil exhibits pharmacokinetic properties including a half-life of 5.93-6.21 h after single oral doses of 40-120 mg. Nortadalafil is identified as an adulterant in dietary supplements .

HY-B0442B

Vardenafil hydrochloride trihydrate 5 Publications Verification	Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-123210

Lodenafil Hydroxyhomosildenafil	Phosphodiesterase (PDE)	Endocrinology
Lodenafil is a potent **phosphodiesterase type 5 (PDE5)** inhibitor for the treatment of erectile dysfunction (ED) .

HY-117605

N-Desmethyl Sildenafil Desmethylsildenafil; UK-103,320	Phosphodiesterase (PDE)	Cardiovascular Disease
N-Desmethyl Sildenafil (Desmethylsildenafil) is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor .

HY-128593

TPN171	Phosphodiesterase (PDE)	Cardiovascular Disease
TPN171 is a potent, selective and oral bioavailable inhibitor of **phosphodiesterase type 5 (PDE5) with an IC₅₀** of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH) .

HY-15025S

Sildenafil-d3 UK-92480-d₃	Phosphodiesterase (PDE)	Cardiovascular Disease Cancer
Sildenafil-d₃ is deuterium labeled Sildenafil-d₃. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.

HY-15025AR

Sildenafil citrate (Standard) UK-92480 citrate (Standard)	Reference Standards Phosphodiesterase (PDE) Autophagy Apoptosis Bacterial	Cardiovascular Disease Cancer
Sildenafil (citrate) (Standard) is the analytical standard of Sildenafil (citrate). This product is intended for research and analytical applications. Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC₅₀ of 5.22 nM.

HY-100933

MY-5445 1 Publications Verification	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology Cancer
MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, **phosphodiesterase type 5 (PDE5), with a K_i of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter ABCG2**, with anti-proliferative effect .

HY-108045

Lodenafil carbonate	Phosphodiesterase (PDE)	Endocrinology
Lodenafil carbonate, a dimer that acts as a proagent delivering Lodenafil in vivo, is an orally active **phosphodiesterase type 5 (PDE5)** inhibitor for the treatment of erectile dysfunction (ED) .

HY-179645

*Phosphodiesterase-IN-5*	Phosphodiesterase (PDE) PKA Interleukin Related TNF Receptor Collagen	Inflammation/Immunology
Phosphodiesterase-IN-5 is a potent, orally active and selective phosphodiesterase 10A (PDE10A) inhibitor with an IC₅₀ of 6.2 nM. Phosphodiesterase-IN-5 shows >1612-fold selectivity over other PDEs. Phosphodiesterase-IN-5 exhibits potent antifibrotic efficacy in a Bleomycin (BLM) (HY-108345)-induced murine model of pulmonary fibrosis (PF) by blocking myofibroblast differentiation via the cAMP/PKA/CREB signaling pathway. Phosphodiesterase-IN-5 can be used for the research of PF .

HY-100650

Carbodenafil	Phosphodiesterase (PDE)	Others
Carbodenafil is a Sildenafil (UK-92480) related compound found in health foods. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM .

HY-119611A

Thioquinapiperifil dihydrochloride KF31327	Phosphodiesterase (PDE)	Metabolic Disease Endocrinology
Thioquinapiperifil dihydrochloride (KF31327), a potent, selective and non-competitive **phosphodiesterase-5 (PDE-5, IC₅₀** of 0.074 nM) inhibitor, is used for sexual enhancement study .

HY-121381

Kuraridine	Phosphodiesterase (PDE)	Others
Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC₅₀=0.64 μM) .

HY-117605R

N-Desmethyl Sildenafil (Standard) Desmethylsildenafil (Standard); UK-103,320 (Standard)	Reference Standards Phosphodiesterase (PDE)	Cardiovascular Disease
N-Desmethyl Sildenafil (Standard) is the analytical standard of N-Desmethyl Sildenafil. This product is intended for research and analytical applications. N-Desmethyl Sildenafil (Desmethylsildenafil) is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor .

HY-B0442AS

Vardenafil-d5 hydrochloride	Endogenous Metabolite Phosphodiesterase (PDE) Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-107191

Sildenafil Mesylate	Phosphodiesterase (PDE)	Cancer
Sildenafil Mesylate is an orally active and selective *phosphodiesterase* type 5 (PDE5) inhibitor. Sildenafil Mesylate can be used in studies of erectile dysfunction and cancer .

HY-15025S1

Sildenafil-d8 UK-92480-d₈	Isotope-Labeled Compounds Phosphodiesterase (PDE) Autophagy Apoptosis	Cardiovascular Disease Cancer
Sildenafil-d₈ is the deuterium labeled Sildenafil. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM .

HY-116808

TPN729	Phosphodiesterase (PDE)	Neurological Disease
TPN729 is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ value of 2.28 nM. TPN729 affects erectile function and it can be used for the research of erectile dysfunction .

HY-119611

Thioquinapiperifil KF31327 free base	Phosphodiesterase (PDE)	Metabolic Disease Endocrinology
Thioquinapiperifil (KF31327 free base), a potent, selective and non-competitive **phosphodiesterase-5 (PDE-5, IC₅₀** of 0.074 nM) inhibitor, is used for sexual enhancement study .

HY-116808B

TPN729MA TPN729 maleate	Phosphodiesterase (PDE)	Neurological Disease
TPN729MA (TPN729 maleate) is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ value of 2.28 nM. TPN729MA affects erectile function and it can be used for the research of erectile dysfunction .

HY-P2424

Cholecystokinin-J CCK-J	Calcium Channel	Others
Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca ²⁺ release .

HY-117605S

N-Desmethyl Sildenafil-d8 Desmethylsildenafil-d₈; UK-103,320-d₈	Phosphodiesterase (PDE) Isotope-Labeled Compounds	Neurological Disease Cancer
N-Desmethyl Sildenafil-d₈ is the deuterium labeled N-Desmethyl Sildenafil (HY-117605). N-Desmethyl Sildenafil is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor .

HY-136520A

(R)-Xanthoanthrafil	Phosphodiesterase (PDE)	Metabolic Disease
(R)-Xanthoanthrafil is a phosphodiesterase-5 (PDE5) inhibitor. (R)-Xanthoanthrafil selectively inhibits PDE5, increasing cyclic guanosine monophosphate (cGMP) levels, leading to smooth muscle relaxation and promoting penile erection. (R)-Xanthoanthrafil can be used to study erectile dysfunction .

HY-114218

BL-122	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
BL-122 is a selective *phosphodiesterase-5* (PDE-5) inhibitor. BL-122 can increase the level of cGMP in the tissue, promote the expression of nitric oxide (NO), and mediate the relaxation of smooth muscle. BL-122 can be used for the researches of inflammation, immunology and cardiovascular disease, such as asthma and hypertension .

HY-N10156

1,3,5-Trihydroxy-4-prenylxanthone	Na+/H+ Exchanger (NHE) Phosphodiesterase (PDE) NO Synthase	Inflammation/Immunology
1,3,5-Trihydroxy-4-prenylxanthone is a Na ⁺/H ⁺ exchange system inhibitor with a minimum inhibitory concentration of 10 μg/mL . 1,3,5-Trihydroxy-4-prenylxanthone is a **phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀** value of 3.0 μM . 1,3,5-Trihydroxy-4-prenylxanthone inhibits Lipopolysaccharide (LPS) (HY-D1056)-induced NO production in RAW264.7 macrophages, and has anti-inflammatory activities .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective **phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀** values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-131473

Desmethyl thiosildenafil	Phosphodiesterase (PDE)	Cardiovascular Disease
Desmethyl thiosildenafil is a **phosphodiesterase type 5 (PDE5)** inhibitor^[1].

HY-N13132

Hellicoside	Phosphodiesterase (PDE) Lipoxygenase	Others
Hellicoside is a natural product that can be obtained from plantain. Hellicoside has inhibitory activity against cAMP phosphodiesterase and 5-lipoxygenase .

HY-132002

Dimethylsildenafil	Drug Derivative	Cardiovascular Disease
Dimethylsildenafil is a derivative of Sildenafil (HY-15025). Sildenafil is a potent **phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀** of 5.22 nM .

HY-136520B

Xanthoanthrafil	Phosphodiesterase (PDE)	Neurological Disease
Xanthoanthrafil is a potent **phosphodiesterase-5 (PDE5) inhibitor, with an IC₅₀** of 3.95 ng/mL. Xanthoanthrafil can be used for the research of erectile dysfunction .

HY-123145

JNJ-10258859	Phosphodiesterase (PDE)	Neurological Disease
JNJ-10258859 is a potent and selective *phosphodiesterase type 5* inhibitor, with a K_i of 0.23 nM. JNJ-10258859 can be used for erectile dysfunction research .

HY-13927S

Acetildenafil-d8	Isotope-Labeled Compounds Drug Derivative	Others
Acetildenafil-d₈ is the deuterium labeled Acetildenafil. Acetildenafil is a structural analog of Sildenafil (HY-15025). Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor.

HY-133991

Desethyl sildenafil Sildenafil impurity C	Phosphodiesterase (PDE)	Cardiovascular Disease Cancer
Desethyl Sildenafil (Sildenafil impurity C) is the impurity of Sildenafil (HY-15025). Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM .

HY-15025AS

Sildenafil citrate-d8 UK-92480 citrate-d8	Phosphodiesterase (PDE) Apoptosis Bacterial Autophagy	Cardiovascular Disease
Sildenafil (citrate)-d₈ is the deuterium labeled Sildenafil citrate . Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC₅₀ of 5.22 nM.

HY-123210R

Lodenafil (Standard) Hydroxyhomosildenafil (Standard)	Reference Standards Phosphodiesterase (PDE)	Endocrinology
Lodenafil (Standard) is the analytical standard of Lodenafil. This product is intended for research and analytical applications. Lodenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED) .

HY-15025R

Sildenafil (Standard) UK-92480 (Standard)	Phosphodiesterase (PDE) Autophagy Apoptosis Bacterial Reference Standards	Cardiovascular Disease Cancer
Sildenafil (Standard) is the analytical standard of Sildenafil. This product is intended for research and analytical applications. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.

HY-13927R

Acetildenafil (Standard)	Reference Standards Drug Derivative	Others
Acetildenafil (Standard) is the analytical standard of Acetildenafil. This product is intended for research and analytical applications. Acetildenafil is a structural analog of Sildenafil (HY-15025). Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor.

HY-15025S3

Sildenafil-d5 UK-92480-d₅	Isotope-Labeled Compounds Autophagy Bacterial Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Sildenafil-d₅ (UK-92480-d₅) is deuterium labeled Sildenafil. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM.

HY-136520S

Xanthoanthrafil-d3	Isotope-Labeled Compounds Phosphodiesterase (PDE)	Neurological Disease
Xanthoanthrafil-d₃ is the deuterium labeled Xanthoanthrafil (HY-136520B). Xanthoanthrafil is a potent phosphodiesterase-5 (PDE5) inhibitor, with an IC₅₀ of 3.95 ng/mL. Xanthoanthrafil can be used for the research of erectile dysfunction .

HY-161290

PDE5-IN-12	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-12 (compound 4h) is a potent **phosphodiesterase-5 (PDE-5) inhibitor with an IC₅₀** of 22 nM. PDE5-IN-12 shows anti-proliferative effects against the aortic cell line .

HY-18253S

Udenafil-d7	Isotope-Labeled Compounds Phosphodiesterase (PDE)	Others Endocrinology
Udenafil-d₇ is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0442

Vardenafil 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18252

Avanafil 1 Publications Verification TA1790	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) is a potent and selective **phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀** values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442A

Vardenafil hydrochloride 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil hydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442B

Vardenafil hydrochloride trihydrate 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-121381

Kuraridine	Chalcones Flavonoids Classification of Application Fields Leguminosae Other Diseases Phenols Polyphenols Sophora flavescens Aiton Plants Disease Research Fields Source Classification	Phosphodiesterase (PDE)
Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC₅₀=0.64 μM) .

HY-N10156

1,3,5-Trihydroxy-4-prenylxanthone	Flavonoids Leguminosae Plants Other Flavonoids Source Classification Erythrina variegata Linn.	Na+/H+ Exchanger (NHE) Phosphodiesterase (PDE) NO Synthase
1,3,5-Trihydroxy-4-prenylxanthone is a Na ⁺/H ⁺ exchange system inhibitor with a minimum inhibitory concentration of 10 μg/mL . 1,3,5-Trihydroxy-4-prenylxanthone is a **phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀** value of 3.0 μM . 1,3,5-Trihydroxy-4-prenylxanthone inhibits Lipopolysaccharide (LPS) (HY-D1056)-induced NO production in RAW264.7 macrophages, and has anti-inflammatory activities .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective **phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀** values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-N13132

Hellicoside	Plantaginaceae Phenols Polyphenols Plantago asiatica L. Plants Source Classification	Phosphodiesterase (PDE) Lipoxygenase
Hellicoside is a natural product that can be obtained from plantain. Hellicoside has inhibitory activity against cAMP phosphodiesterase and 5-lipoxygenase .

HY-B0442C

Vardenafil dihydrochloride	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil dihydrochloride is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-B0442CR

Vardenafil dihydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442AR

Vardenafil hydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite Reference Standards
Vardenafil (hydrochloride) (Standard) is the analytical standard of Vardenafil (hydrochloride). This product is intended for research and analytical applications. Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442R

Vardenafil (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of *phosphodiesterase-5* (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-W049735R

N,N,O-Tridesmethylvenlafaxine (Standard)	Monophenols Phenols Endogenous metabolite Source Classification	Drug Metabolite Reference Standards Endogenous Metabolite
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442BR

Vardenafil hydrochloride trihydrate (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-18252R

Avanafil (Standard) TA1790 (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-113972R

Methyl mycophenolate (Standard)	Structural Classification Monophenols Microorganisms Marine natural products Phenols Marine microorganism	Reference Standards Others
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

Cat. No.	Product Name	Chemical Structure

HY-15025S

Sildenafil-d3
Sildenafil-d₃ is deuterium labeled Sildenafil-d₃. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.

HY-B0442AS

Vardenafil-d5 hydrochloride

Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-15025S1

Sildenafil-d8
Sildenafil-d₈ is the deuterium labeled Sildenafil. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM .

HY-117605S

N-Desmethyl Sildenafil-d8
N-Desmethyl Sildenafil-d₈ is the deuterium labeled N-Desmethyl Sildenafil (HY-117605). N-Desmethyl Sildenafil is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor .

HY-13927S

Acetildenafil-d8
Acetildenafil-d₈ is the deuterium labeled Acetildenafil. Acetildenafil is a structural analog of Sildenafil (HY-15025). Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor.

HY-15025AS

Sildenafil citrate-d8
Sildenafil (citrate)-d₈ is the deuterium labeled Sildenafil citrate . Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC₅₀ of 5.22 nM.

HY-15025S3

Sildenafil-d5
Sildenafil-d₅ (UK-92480-d₅) is deuterium labeled Sildenafil. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM.

HY-136520S

Xanthoanthrafil-d3
Xanthoanthrafil-d₃ is the deuterium labeled Xanthoanthrafil (HY-136520B). Xanthoanthrafil is a potent phosphodiesterase-5 (PDE5) inhibitor, with an IC₅₀ of 3.95 ng/mL. Xanthoanthrafil can be used for the research of erectile dysfunction .

HY-18253S

Udenafil-d7
Udenafil-d₇ is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research .

HY-15025S2

Sildenafil-d3-1
Sildenafil-d3-1 (UK-92480-d3-1) is deuterium labeled Sildenafil-d₃. Sildenafil (UK-92480) is a potent **phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀** of 5.22 nM.

HY-B0442S

Vardenafil-d5

Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction .

HY-18252S3

Avanafil-13C5

Avanafil- ¹³C₅ (TA1790- ¹³C₅) is ¹³C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252S1

Avanafil-13C5,15N,d2

Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-W751650

Sildenafil-d3 citrate
Sildenafil-d₃ citrate (UK-92480-d₃ citrate) is the deuterium labeled Sildenafil citrate (HY-15025A). Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC₅₀ of 5.22 nM.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks